Abstract 179P
Background
Whether postoperative adjuvant transarterial chemoembolization (PA-TACE) can prolong overall survival (OS) in patients with resected hepatocellular carcinoma (HCC) remains confusion. We aimed to assess and compare the efficacy of PA-TACE and surgery alone in patients with resected HCC.
Methods
Data from patients who underwent surgery were selected and collected for retrospectively analysis. A propensity-score 1:1 matching analysis was performed. The overall survival was analyzed by the Kaplan-Meier method, and survival outcomes for patients who underwent PA-TACE were compared with those who underwent surgery alone.
Results
A total 286 patients (PA-TACE vs surgery alone, 143:143) were identified and selected after a propensity-score 1:1 matching analysis. No significant difference was observed in each variable in the matched data. And, all Kaplan-Meier curves for overall survival between PA-TACE and surgery alone group showed significance before and after propensity score matching (P = 0.0065 and P < 0.001, respectively). Subgroup analysis showed patients with low BCLC stage and low albumin-bilirubin grade had a better overall survival in the PA-TACE group.
Conclusions
Compared to surgery alone, PA-TACE could prolonger overall survival in patients with resected HCC, especially for who with low BCLC stage and/or low albumin-bilirubin grade.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Xiujun Cai.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
259P - The BOT patients fail to benefit from surgical staging procedures in prognosis and fertility outcomes: A retrospective analysis
Presenter: Li Na
Session: Poster display session
Resources:
Abstract
260P - Malignant ovarian germ cell tumours (MOGCT): Treatment results of 149 pts
Presenter: Dzhennet Chekini
Session: Poster display session
Resources:
Abstract
261P - Ovarian germ cell tumours - challenges and outcomes from a tertiary care centre in South India
Presenter: Vishnu Sreedath
Session: Poster display session
Resources:
Abstract
262P - Gestational trophoblastic tumours: Experience of the medical oncology department Hassan II University Hospital-Morocco about 29 cases
Presenter: Karima Oualla
Session: Poster display session
Resources:
Abstract
263TiP - ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled phase III study of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib + the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
264TiP - ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA¬-nonmutated advanced epithelial ovarian cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
265TiP - KEYNOTE-826: A phase III randomized study of chemotherapy with or without pembrolizumab for first-line treatment of persistent, recurrent, or metastatic cervical cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
271P - Comparison between CHOP like regimens and DAEPOCH with or without Rituximab in adult high grade B cell lymphoma NOS; A retrospective study from a tertiary cancer hospital in South India
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
272P - Melatonin increases the chemosensitivity of diffuse large Bell lymphoma cells to Epirubicin by inhibiting P-glycoprotein expression via the NF-κB pathway
Presenter: Xiuhua Sun
Session: Poster display session
Resources:
Abstract
273P - MALT1- A20 and NF-κB expression pattern in patients with non-Hodgkin lymphomas
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract